High expression levels of SMAD1 were highly correlated with favorable OS of gastric cancer patients (HR = 0.55 (0.42–0.72), P = 1.2e-05, Figure 1(a)), gastrointestinal cancer patients (HR = 0.5 (0.35–0.72), P = 0.00014, Figure 1(b)) and diffuse gastric cancer patients (HR = 0.47 (0.3–0.72), P = 0.00038 (Figure 1(c)). This evidence concerns the gene SMAD1 and gastric cancer.